These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof. Securities and Exchange Commission (SEC) and in subsequent lings made by Moderna with the SEC, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These risks, uncertainties, and other factors include those risks and uncertainties described under the heading 'Risk Factors' in Moderna's most recent Annual Report on Form 10-K filed with the U.S. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. to support the commercialization of the Moderna's COVID-19 Vaccine, Spikevax across Latin America and the scope of countries covered under that agreement, and plans to expand the Company's commercial presence to ten additional markets in 2022. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company's distribution service agreement with Adium Pharma S.A. To learn more, visit Forward Looking Statements Moderna has been named a top biopharmaceutical employer by Science for the past seven years. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most-effective vaccines against the COVID-19 pandemic. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. In Latin America, Moderna has established bilateral and supranational supply agreements in 15 countries. In 2021, 807 million doses of Moderna's COVID-19 vaccine were shipped globally, with approximately 25% of those doses shipped to low- and middle-income markets. Regulators have approved Moderna's COVID-19 vaccine in more than 70 markets, including Canada, Japan, the European Union, the UK, and Israel. These partnerships and the expansion of our global commercial footprint position Moderna to play an important role in providing healthcare security against COVID-19 and future vaccine-preventable diseases.' 'A presence in Latin America is a key part of our global commercial strategy. 'Our new partnership with Adium will help ensure broad access and delivery of our Moderna COVID-19 vaccine to people across Latin America,' said Stéphane Bancel, Chief Executive Officer of Moderna.

The agreement covers 18 countries in Latin America, including Brazil, Mexico, Colombia, and Argentina. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced a distribution service agreement with Adium Pharma S.A., a leading private Latin American pharmaceutical company, to support the commercialization of the Moderna COVID-19 vaccine, Spikevax across Latin America. Moderna also supplies the Company's COVID-19 vaccine to 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries through GAVI, the Vaccine Alliance agreementĬAMBRIDGE, MA / ACCESSWIRE / Febru/ Moderna, Inc.

Moderna has a commercial footprint in 56 countries across the world through direct presence and distributors and plans expansion in ten additional markets in 2022

Adium yahoo